Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
about
Advances in antibiotic therapy in the critically illUrosepsis--Etiology, Diagnosis, and TreatmentAntibiotic stewardship in the intensive care unit.Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullinQuality of blood culture testing - a survey in intensive care units and microbiological laboratories across four European countriesEmerging concepts in optimizing antimicrobial therapy of septic shock: speed is life but a hammer helps tooMuscle ultrasound for early assessment of critical illness neuromyopathy in severe sepsisAppropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net.Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shockPrediction of multiple infections after severe burn trauma: a prospective cohort study.Treatment of bloodstream infections in ICUsThe Japanese guidelines for the management of sepsis.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceExogenous carbon monoxide attenuates inflammatory responses in the small intestine of septic mice.Overview of progresses in critical care medicine 2012.The epidemiology of acute organ system dysfunction from severe sepsis outside of the intensive care unitNext-generation sequencing diagnostics of bacteremia in septic patients.Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28Day MortalityPreclinical models of overwhelming sepsis implicate the neural system that encodes contextual fear memory.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.Hemoadsorption by CytoSorb in septic patients: a case series.Update in pulmonary infections 2012.Update in sepsis 2012.Respiratory review of 2013: critical care medicine.How outcomes are defined in clinical trials of mechanically ventilated adults and children.Antimicrobial stewardship of β-lactams in intensive care units.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Management of severe sepsis: advances, challenges, and current status.Rapid identification of pathogens in positive blood culture of patients with sepsis: review and meta-analysis of the performance of the sepsityper kit.The brain at risk: the sepsis syndrome and lessons from preclinical experiments.The use and risks of antibiotics in critically ill patients.Pathogenic, immunologic, and clinical aspects of sepsis - update 2016.Control groups in recent septic shock trials: a systematic review.Recycling antibiotics into GUMBOS: a new combination strategy to combat multi-drug-resistant bacteria.Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies.Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation.Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.[Severe pneumonia in the intensive care unit].Relevance of Candida and other mycoses for morbidity and mortality in severe sepsis and septic shock due to peritonitis.
P2860
Q26749328-FF83D52A-352A-46F8-91B7-06732658B760Q28078523-5B967931-1A41-4A71-B5AA-A5D4FBF45EE9Q30408712-55CDBEBB-43BC-4BFF-99E8-08DB6F6687BBQ33749965-F77CCA02-C18F-46C1-9D3C-3B4FACBD3F70Q33750097-CEAEBE72-3A58-42D7-A552-5AD90259BFEDQ33752132-F5DEEF61-65F0-4E0D-B435-A9094A552EF4Q33754428-B081E646-6D35-40CD-A5C8-A0DD27147148Q33843533-F6DFC870-E1A7-44FD-8806-9A92A359ED42Q34645044-09358C7A-F718-4F96-9D1E-6D7639341AB9Q34825134-6265E05C-4455-4ADB-8D5B-678B83BAC69EQ34896896-05F5B74B-E00E-4A89-BA22-0BB867DC50E4Q35107094-15C211C4-5FE9-4E53-9FFE-9B48AF04C226Q36089167-D4DA8CAA-BE06-4E9E-B8F9-4CDE3CF816FCQ36357446-D012B5CA-1FF5-4530-8BF9-5DCCC4594F45Q36753909-7AAF5589-87F7-44C9-A25E-5A8FC04388C2Q36831863-AF1C241E-005B-45C2-8458-D5F3DFF7DB95Q37059591-E36C1812-7B3D-4A69-831A-EDFC17980E15Q37363505-27373523-6533-4406-971E-07AB70F6807AQ37541042-95295CDE-B99A-4E62-8402-7DB064EA9FD9Q37563029-CA8B0FEB-493A-422C-9502-DEB19164B55CQ37643662-3A7F8AD8-1F3D-4BD2-A0EA-0CE799998CAAQ37721770-9D02ACA2-1479-4553-8115-D298547A8CECQ38106995-9095150E-2C53-4A1A-9FB1-87FE6E1865B2Q38114486-7BD5930A-AFC2-4B6D-86C8-48CAAF4A5F84Q38129055-ED89B110-A476-4DB6-8606-420B615A61BAQ38186788-2109DE55-8BEE-4814-80C4-D7B408BFB7C4Q38198157-30E8EDA9-4722-4A4C-A55E-8C9E2420D63AQ38384662-13739880-1A0D-4ECF-B0B9-B55D4779BBD7Q38450665-C356F208-2A7D-4EB0-8B20-51215C4A8AB8Q38497276-9CEE4C0B-F11C-4B5F-9004-D29CC0724A33Q38600325-AECE7979-F064-4AB3-A7EC-24375753C0F0Q38767901-F8E464C8-C9F3-4B90-92BE-0D7C3F3A76A6Q38830793-7B2E0C1C-52A6-4CA3-9472-BCBAE6FF97A6Q38838734-723D4263-791D-4AC0-BCD6-32EF3DDA45A7Q38888005-0CB94AC5-96A7-42A7-B946-4E738D9D8913Q40043861-0324F9D9-D4F7-4083-AEBB-9DB0D68F7E27Q40088340-CF9FE2A7-B854-4A87-AAEF-6EF36114D440Q40474926-822328D6-B7ED-4069-92C2-BA91B2EA519EQ40763182-787162D7-0C12-4176-8360-433670003609Q41203002-EED8C6EA-73EE-4C31-BAEA-754E680771E2
P2860
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effect of empirical treatment ...... re sepsis: a randomized trial.
@ast
Effect of empirical treatment ...... re sepsis: a randomized trial.
@en
Effect of empirical treatment ...... re sepsis: a randomized trial.
@nl
type
label
Effect of empirical treatment ...... re sepsis: a randomized trial.
@ast
Effect of empirical treatment ...... re sepsis: a randomized trial.
@en
Effect of empirical treatment ...... re sepsis: a randomized trial.
@nl
prefLabel
Effect of empirical treatment ...... re sepsis: a randomized trial.
@ast
Effect of empirical treatment ...... re sepsis: a randomized trial.
@en
Effect of empirical treatment ...... re sepsis: a randomized trial.
@nl
P2093
P50
P356
P1476
Effect of empirical treatment ...... re sepsis: a randomized trial.
@en
P2093
Andreas Meier-Hellmann
Andreas Weyland
Armin Seibel
Axel Nierhaus
Christian Putensen
Evelyn Kuhnt
Frank Bloos
Friedhelm Bach
German Study Group Competence Network Sepsis (SepNet)
Gernot Marx
P304
P356
10.1001/JAMA.2012.5833
P407
P50
P577
2012-06-01T00:00:00Z